cerep (ALCER) Details

Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services, as well as solutions for drug discovery. The company offers various research services, including compound management, high-throughput screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK; and custom research services comprising assay development, profile design, and data interpretation, as well as provide scientist-to-scientist communications to understand and address client’s needs. Its platforms cover a range of target classes, such as ADME-Tox related targets, GPCRs, various enzymes, transporters, nuclear receptors, and ion channels, which employ methods and assay types comprising radioligand binding assays, calcium mobilization and cAMP measurement using TRFRET, transporter/uptake assays, and bioluminescent and other fluorescent-based assays. The company also offers assay development services that include a range of assays and technologies adapted to client’s specific projects and needs. In addition, it provides BioPrint profiles and services, a homogenous pharmacology and ADME database comprising data sets, such as chemical descriptors, compound descriptors, and in vivo effects of drugs, which offer a resource for supporting decision making in drug discovery. The company provides its services to pharmaceutical and biotechnological companies worldwide. Cerep SA was founded in 1989 and is headquartered in Celle l'Evescault, France.

cerep (ALCER) Top Compensated Officers